CN105392886B - 用于抑制切昆贡亚病毒的RNAi剂 - Google Patents

用于抑制切昆贡亚病毒的RNAi剂 Download PDF

Info

Publication number
CN105392886B
CN105392886B CN201480037556.6A CN201480037556A CN105392886B CN 105392886 B CN105392886 B CN 105392886B CN 201480037556 A CN201480037556 A CN 201480037556A CN 105392886 B CN105392886 B CN 105392886B
Authority
CN
China
Prior art keywords
chikungunya virus
sirna
nivsi
rnai
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480037556.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105392886A (zh
Inventor
D·帕拉沙尔
A·V·阿兰卡莱
S·M·佩甘卡
S·库马尔
D·M·戈卡莱
B·A·苏迪普
S·S·欣德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indian Council of Medical Research
Original Assignee
Indian Council of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Council of Medical Research filed Critical Indian Council of Medical Research
Publication of CN105392886A publication Critical patent/CN105392886A/zh
Application granted granted Critical
Publication of CN105392886B publication Critical patent/CN105392886B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480037556.6A 2013-07-02 2014-07-02 用于抑制切昆贡亚病毒的RNAi剂 Active CN105392886B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1960/DEL/2013 2013-07-02
PCT/IN2014/000441 WO2015001570A1 (en) 2013-07-02 2014-07-02 Rnai agent for inhibition of chikungunya virus
IN1960DE2013 IN2013DE01960A (enExample) 2013-07-02 2014-07-02

Publications (2)

Publication Number Publication Date
CN105392886A CN105392886A (zh) 2016-03-09
CN105392886B true CN105392886B (zh) 2019-10-22

Family

ID=51383914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480037556.6A Active CN105392886B (zh) 2013-07-02 2014-07-02 用于抑制切昆贡亚病毒的RNAi剂

Country Status (6)

Country Link
US (1) US9574195B2 (enExample)
EP (1) EP3017046B1 (enExample)
CN (1) CN105392886B (enExample)
AU (1) AU2014285701C1 (enExample)
IN (1) IN2013DE01960A (enExample)
WO (1) WO2015001570A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190572A (es) * 2017-07-06 2020-05-23 Arrowhead Pharmaceuticals Inc AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Administration of E2 and NS1 siRNAs inhibit Chikungunya virus replication in vitro and protects mice iinfected with the virus;DEEPTI等;《PLOS NEGLECTED TROPICAL DISEASES》;20130905;第7卷(第9期);摘要 *
Expression of plasmid-based shRNA against the E1 and nsP1 Gene effiective silenced chikungunya virus replication;SHIRLEY等;《PLOS ONE》;20121008;第7卷(第10期);摘要 *
RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells;Paban等;《Biochemical and Biophysical research communications》;20080919;摘要，表1 *

Also Published As

Publication number Publication date
CN105392886A (zh) 2016-03-09
AU2014285701B2 (en) 2021-04-01
WO2015001570A1 (en) 2015-01-08
EP3017046A1 (en) 2016-05-11
US20160145621A1 (en) 2016-05-26
AU2014285701A1 (en) 2016-01-21
IN2013DE01960A (enExample) 2015-06-26
US9574195B2 (en) 2017-02-21
EP3017046B1 (en) 2019-09-11
AU2014285701C1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
Parashar et al. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus
Xie et al. Inhibition of reporter gene and Iridovirus-tiger frog virus in fish cell by RNA interference
Wu et al. MiR-506 inhibits PRRSV replication in MARC-145 cells via CD151
JP2005521393A5 (enExample)
Yang et al. Small interfering RNAs targeting the rabies virus nucleoprotein gene
Thi et al. siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
Gotesman et al. In vitro inhibition of Cyprinid herpesvirus-3 replication by RNAi
Fouad et al. In-vitro inhibition of spring viremia of carp virus replication by RNA interference targeting the RNA-dependent RNA polymerase gene
Hou et al. MiR-3470b promotes bovine ephemeral fever virus replication via directly targeting mitochondrial antiviral signaling protein (MAVS) in baby hamster Syrian kidney cells
Bhomia et al. Artificial microRNAs can effectively inhibit replication of Venezuelan equine encephalitis virus
Tan et al. Enhanced potency and efficacy of 29-mer shRNAs in inhibition of Enterovirus 71
Meshram et al. Evaluation of single and dual siRNAs targeting rabies virus glycoprotein and nucleoprotein genes for inhibition of virus multiplication in vitro
Karothia et al. Vector derived artificial miRNA mediated inhibition of West Nile virus replication and protein expression
Pozzuto et al. Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir
Schyth et al. Antiviral activity of small interfering RNAs: specificity testing using heterologous virus reveals interferon-related effects overlooked by conventional mismatch controls
CN105392886B (zh) 用于抑制切昆贡亚病毒的RNAi剂
CN102154290B (zh) 用于抑制流行性乙型脑炎病毒的siRNA
Eszterhas et al. Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants
Scott et al. Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs
He et al. In vitro inhibition of transmissible gastroenteritis coronavirus replication in swine testicular cells by short hairpin RNAs targeting the ORF 7 gene
Arani et al. In vitro Inhibition of Border Disease Virus Replication With Lentivirus-Mediated shRNAs
Vig et al. Secondary RNA structure and its role in RNA interference to silence the respiratory syncytial virus fusion protein gene
CN103045592A (zh) 与流感病毒复制相关的长链非编码核酸片段以及它们的应用
Chen et al. Ago-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi
KR101077188B1 (ko) 구제역 바이러스 억제를 위한 ｓｉＲＮＡ를 발현하는 재조합 아데노바이러스

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant